Heterodinucleoside phosphates of 5-Fluorodeoxyuridine and Arabinofuranosylcytosine - New drugs in cancer chemotherapy?

In Vivo

Volumn 19, Issue 1, 2005, Pages 205-214

  Saiko, Philipp ^a   Horvath, Zsuzsanna ^a   Jaeger, Walter ^b   Schott, Herbert ^c   Fritzer Szekeres, Monika ^a   Szekeres, Thomas ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

5 Fluorodeoxyuridine; Arabinofuranosylcytosine; Heterodinucleoside phosphates

Indexed keywords

5 ETHYNYLURACIL; ANTHRACYCLINE DERIVATIVE; ANTIESTROGEN; CAPECITABINE; CHLOROETHYLNITROSOUREA DERIVATIVE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; CYTARABINE TRIPHOSPHATE; DEXAMETHASONE; FLOXURIDINE; FLOXURIDINE PHOSPHATE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE TRIPHOSPHATE; FOLIC ACID DERIVATIVE; FOLINIC ACID; GEMCITABINE; IRINOTECAN; LEVAMISOLE; LIPOSOME; MELPHALAN; METHOTREXATE; ORZEL; OXALIPLATIN; TIOGUANINE; UFT; UNINDEXED DRUG; URACIL ARABINOSIDE; VINCA ALKALOID;

ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBELLUM DISEASE; CLINICAL TRIAL; COLON CANCER; CONJUNCTIVITIS; DERMATITIS; DIARRHEA; DRUG ABSORPTION; DRUG ACTIVATION; DRUG BINDING; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TRANSPORT; DUODENUM ULCER; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; JAUNDICE; LIVER DYSFUNCTION; MEGALOBLASTIC ANEMIA; MUCOSA INFLAMMATION; NAIL DISEASE; NONHUMAN; PNEUMONIA; SCLEROSING CHOLANGITIS; STOMACH ULCER; WESTERN HEMISPHERE;

EID: 16244375237     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Chabner BA: Clinical strategies for cancer treatment: the role of drugs. In: Cancer Chemotherapy. Principles and Practice. (Chabner BA and Collins JM, eds). Philadelphia, Lippincott, 1990, pp 1-15.
2. Henderson EH and Samaha RJ: Evidence that drugs in multiple combinations have materially advanced the treatment of human malignancies. Cancer Res 29: 2272-2280, 1969.
3. Erlichman C, Fine S, Wong A and Elhakim T: A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6: 469-475, 1988.
4. Wittes RE: Adjuvant chemotherapy - clinical trials and laboratory models. Cancer Treat Rep 70: 87-103, 1986.
5. Martin DS: The scientific basis for adjuvant chemotherapy. Cancer Treat Rev 8: 169-189, 1981.
6. Berg SL, Grisell DL, DeLaney TF and Balis FM: Principles of treatment of pediatric solid tumors. Pediatr Clin North Am 38: 249-267, 1991.
7. Goldie JH and Coldman AJ: Theoretical considerations regarding the early use of adjuvant chemotherapy. Recent Res Cancer Res 103: 30-35, 1986.
8. Early Breast Cancers Trialists' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. N Eng J Med 319: 1681-1692, 1988.
9. Weiss GR and Coltman CA: Conference summary overview. In Adjuvant Therapy of Cancer VI (Salmon SE, ed). Philadelphia, Saunder, 1990, pp 623-629.
10. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC and Glick JH: Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Eng J Med 322: 352-358, 1990.
11. O'Connell MJ, Gunderson LL and Fleming TR: Surgical adjuvant therapy of rectal cancer. Semin Oncol 15: 138-145, 1988.
12. Gilewski T and Bitran JD: Adjuvant chemotherapy. In: The Chemotherapy Source Book (Perry MC, ed). Baltimore, Williams and Wilkins, 1996, pp 79-100.
13. Ragaz J, Baird R, Rebbeck P et al: Preoperative (neoadjuvant-PRE) versus postoperative (POST) adjuvant chemotherapy (CT) for stage I-II breast cancer (SI-II BC). Long-term analysis of British Columbia randomized trial. Proc Am Soc Clin Oncol 16: 142, 1997.
14. Belani CP, Luketich J, Landreneau RJ et al: Efficacy of paclitaxel, 5-fluorouracil and cisplatin (PFT) regimen for carcinoma of the esophagus. Proc Am Soc Oncol 16: 283, 1997.
15. Wanebo HJ, Chougule P, Akerley W et al: Preoperative paclitaxel, carboplatin and radiation in advanced head and neck cancer (stage III and IV) induces a high rate of complete pathologic response (CR) at the primary site and high rate of organ preservation. Proc Am Soc Clin Oncol 16: 391, 1997.
16. Riddell RH: Inflammatory bowel disease and colorectal cancer. In: Cancer of the Colon, Rectum and Anus (Cohen AM, Winawer SJ, Friedman MA, Gunderson LL, eds). New York, McGraw-Hill, 1995, pp 105-119.
17. Winawer SJ and Shike M: Dietary factors in colorectal cancer and their possible effects in earlier stages on hyperproliferation and adenoma formation. J Natl Cancer Inst 84: 74-75, 1992.
18. Giovannucci E, Stampfer MJ, Colditz G, Rimm EB and Willet WC: Relationship of diet to risk of colorectal adenoma in men. J Natl Cancer Inst 84: 91-98, 1992.
19. Martinez ME, Giovannucci EL, Colditz GA, Stampfer MJ, Hunter DJ, Speizer FE, Wing A and Willett WC: Calcium, vitamin D, and the occurrence of colorectal cancer among women. J Natl Cancer Inst 88: 1375-1382, 1996.
20. Moertel CG, Fleming TR, MacDonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC and Glick JH: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321-326, 1995.
21. Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, Jones J, Mamounas EP, Ore L and Petrelli NJ: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11: 1879-1887, 1993.
22. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939-944, 1995.
23. Zaniboni A: Adjuvant chemotherapy in colorectal cancer with high-dose leucovorin and fluorouracil: impact on disease-free survival and overall survival. J Clin Oncol 15: 2432-2441, 1997.
24. O_Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ and Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: 246-250, 1997.
25. Bajetta E, Carnaghi C, Somma L and Stampino CG: A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease. Tumori 82: 450-452, 1996.
26. Feliu J, Gonzalez Baron M, Zamora P, Garcia Alfonso P, Garcia Giron C, Blanco E, Belon J, Garrido P, Jara C, Ruiz A, Vincent JM and Espinosa E: Experience of Oncopaz Cooperative Group with oral fluoropyrimidines in tumors of the stomach, lung, head and neck, and breast. Oncology 54 Suppl 1: 30-37, 1997.
27. Takechi T, Nakano K, Uchida J, Mita A, Toko, K, Takeda S, Unemi N and Shirasaka T: Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39: 205-211, 1997.
28. Keyomarsi K and Moran RG: Folinic acid augmentation of the effects of fluoropyrimidine on murine and human leukemic cells. Cancer Res 46: 5229-5235, 1986.
29. Sotos GA and Allegra CJ: Biochemical modulation of cancer chemotherapy. In: Principles of Antineoplastic Drug Development and Pharmacology (Schilsky RL, Milano GA, Ratain MJ, eds). New York, Dekker, 1996, pp 143-187.
30. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL and Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
31. Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu JJ, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz JF and Ychou M: Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 7: 95-98, 1996.
32. Becouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-Andre G and Rougier P: Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol 16: 2739-2744, 1998.
33. Kohn KW, Jackman J and O'Connor PM: Cell cycle control and chemotherapy. J Cell Biochem 54: 440-452, 1994.
34. O'Connor PM and Kohn KW: A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin Cancer Biol 3: 409-416, 1992.
35. 14 by pre-neoplastic rat liver. Cancer Res 14: 119-126, 1954.
36. Sommer H and Santi DV: Purification and amino acid analysis of an active site peptide from thymidylate synthetase containing covalently bound 5-fluoro-2′-deoxyuridylate and methylenete-trahydrofolate. Biochem Biophys Res Commun 57: 689-695, 1974.
37. Mandel G: The incorporation of 5-fluorouracil into RNA and its molecular consequences. In: Progress in Molecular and Subcellular Biology (Hahn FE, ed). Berlin Heidelberg New York, Springer, 1969, pp 82-135.
38. Ghoshal K and Jacob ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol 53: 1569-1575, 1997.
39. Gutheil J and Kearns C: Antimetabolites. In: The Chemotherapy Source Book (Perry MC, ed). Baltimore, Williams and Wilkins, 1996, pp 317-343.
40. Kinsella AR, Smith D and Pickard M: Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br J Cancer 75: 935-945, 1997.
41. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 43: 3466-3492, 1983.
42. Pickard M, Dive C and Kinsella AR: Differences in resistance to 5-fluorouracil as a function of cell cycle delay and not apoptosis. Br J Cancer 72: 1389-1396, 1995.
43. Fischel JL, Formento P, Etienne MC, Spector T, Renee N and Milano G: Dual modulation of 5-fluorouracil cytotoxicity using folinic acid with a dihydropyrimidine dehydrogenase inhibitor. Biochem Pharmacol 53: 1703-1709, 1997.
44. Ensminger WD and Gyves JW: Clinical pharmacology of hepatic arterial chemotherapy. Semin Oncol 10: 176-182, 1983.
45. Hohn DC, Stagg RJ, Friedman MA, Hannigan JF Jr, Rayner A, Ignoffo RJ, Acord P and Lewis BJ: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7: 1646-1654, 1989.
46. Kemeny N, Daly J, Reichman B, Geller N, Botet J and Oderman P: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107: 459-465, 1987.
47. Martin JK Jr, O'Connell MJ, Wieand HS, Fitzgibbons RJ Jr, Mailliard JA, Rubin J, Nagorney DM, Tschetter LK and Krook JE: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg 125 1022-1027, 1990.
48. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M and Steinberg SM: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206: 685-693, 1987.
49. Kemeny MM, Goldberg D, Beatty JD, Blayney D, Browning S, Doroshow J, Ganteaume L, Hill RL, Kokal WA and Riihimaki DU: Results of a prospective randomized trial of continuous regional chemotherapy and hepatic resection as treatment of hepatic metastases from colorectal primaries. Cancer 57: 492-498, 1986.
50. Rougier P, Laplanche A, Huguier M, Hay JM, Ollivier JM, Escat J, Salmon R, Julien M, Roullet Audy JC and Gallot D: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 10: 1112-1118, 1992.
51. Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-258, 1996.
52. Cozzarelli NR: The mechanism of action of inhibitors of DNA synthesis. Annu Rev Biochem 46: 641-668, 1977.
53. Grant S and Cadman E: Modulation of 1-beta-D-arabinofurano sylcytosine metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment. Cancer Res 42: 3550-3556, 1982.
54. Rauko P, Bauer W, Horvath Z, Höchtl T, Saiko P, Karl D, Schott H, Fritzer-Szekeres M, Novotny L and Szekeres T: Combination effects of Ara-C and 5-fluorodeoxyuridine against leukemia cells in vitro and in mice. Anticancer Res 23: 3841-3846, 2003.
55. Schwendener RA, Supersaxo A, Rubas W, Weder HG, Hartmann HR, Schott H, Ziegler A, Hengartner H: 5′-O-Palmitoyl- and 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine - novel lipophilic analogues of 5′-fluoro-2′-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results. Biochem Biophys Res Commun 126: 660-666, 1985.
56. Schwendener RA, Friedl K, Depenbrock H, Schott H and Hanauske AR: In vitro activity of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine (NOAC), a new lipophilic derivative of 1-beta-D-arabinofuranosylcytosine on biopsized clonogenic human tumor cells and hematopoietic precursor cells. Invest New Drugs 19: 203-210, 2001.
57. Horber DH, Cattaneo-Pangrazzi RM, von Ballmoos P, Schott H, Ludwig PS, Eriksson S, Fichtner I and Schwendener RA: Cytotoxicity, cell-cycle perturbations and apoptosis in human tumor cells by lipophilic N4-alkyl-1-beta-D-arabinofuranosylcytosine derivatives and the new heteronucleoside phosphate dimer arabinocytidylyl- (5′->5′)-N4-octadecyl-1 -beta-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 126: 311-319, 2000.
58. Cattaneo-Pangrazzi RM, Schott H, Wunderli-Allenspach H, Rothen-Rutishauser B, Guenthert M and Schwendener RA: Cell-cycle arrest and p53-independent induction of apoptosis in vitro by the new anticancer drugs 5-FdUrd-P-FdCydOct and dCydPam-P-FdUrd in DU-145 human prostate cancer cells. J Cancer Res Clin Oncol 126: 247-256, 2000.
59. Koning GA, Gorter A, Scherphof GL and Kamps JA: Antiproliferative effect of immunoliposomes containing 5-fluoro-deoxyuridine-dipalmitate on colon cancer cells. Br J Cancer 80: 1718-1725, 1999.
60. Koller-Lucae SK, Schott H and Schwendener RA: Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabino-furanosylcytosine in Daudi lymphoma cells. Br J Cancer 80: 1542-1549, 1999.
61. Koller-Lucae SK, Suter MJ, Rentsch KM, Schott H and Schwendener RA: Metabolism of the new liposomal anticancer drug N4-octadecyl-1-beta-D-arabinofuranosyl-cytosine in mice. Drug Metab Dispos 27: 342-350, 1999.
62. Rentsch KM, Schwendener RA, Schott H and Hanseler E: Pharmacokinetics of N4-octadecyl-1-beta-D-arabinofurano sylcytosine in plasma and whole blood after intravenous and oral administration to mice. J Pharm Pharmacol 49: 1076-1081, 1997.
63. Koller-Lucae SK, Schott H and Schwendener RA: Interactions with human blood in vitro and pharmacokinetic properties in mice of liposomal N4-octadecyl-1-beta-D-arabinofuranosylcytosine, a new anticancer drug. J Pharm Pharmacol 282: 1572-1580, 1997.
64. Schott H and Schwendener RA: Synthesis and structure-activity studies in vivo of liposomal phospholipid-N4-palmitoyl- and N4-hexadecyl-1-beta-D-arabino-furanosylcytosine conjugates. Anticancer Drug Des 11: 451-462, 1996.
65. Schwendener RA and Schott H: Lipophilic 1-beta-D-arabinofuranosylcytosine derivatives in liposomal formulations for oral and parenteral antileukemic therapy in the murine L1210 leukemia model. J Cancer Res Clin Oncol 122: 723-726, 1996.
66. Schwendener RA, Horber DH, Odermatt B and Schott H: Oral antitumour activity in murine L1210 leukemia and pharmacological properties of liposome formulations of N4-alkyl derivatives of 1-beta-D-arabinofuranosylcytosine. J Cancer Res Clin Oncol 122: 102-108, 1996.
67. Schott H and Schwendener RA: Synthesis of liposomal phospholipid-(N4-palmitoyl-1-beta-D-arabinofuranosylcytosine) conjugates and evaluation of their cytostatic activity against L1210 murine leukemia. Liebigs Ann 365-369, 1996.
68. Schwendener RA and Schott H: Treatment of L1210 murine leukemia with liposome-incorporated N4-hexadecyl-1-beta-D-arabinofuranosylcytosine. Int J Cancer 51: 466-469, 1992.
69. Supersaxo A, Rubas W, Hartmann HR, Schott H, Hengartner H and Schwendener RA: The antitumour effect of lipophilic derivatives of 5-fluoro-2′-deoxyuridine incorporated into liposomes. J Microencapsul 5: 1-11, 1988.
70. Schwendener RA, Supersaxo A, Rubas W, Weder HG, Hartmann HR, Schott H, Ziegler A and Hengartner H: 5′-O-Palmitoyl- and 3′,5′-O-dipalmitoyl-5-fluoro-2′-deoxyuridine--novel lipophilic analogues of 5′-fluoro-2′-deoxyuridine: synthesis, incorporation into liposomes and preliminary biological results. Biochem Biophys Res Commun 126: 660-666, 1985.
71. Cattaneo-Pangrazzi RM, Schott H and Schwendener RA: The novel heterodinucleoside dimer 5-FdU-NOAC is a potent cytotoxic drug and a p53-independent inducer of apoptosis in the androgen-independent human prostate cancer cell lines PC-3 and DU-145. Prostate 45: 8-18, 2000.
72. Carson DA and Ribeiro JM: Apoptosis and disease. Lancet 341: 1251-1254, 1993.
73. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78: 539-542, 1994.
74. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 11: 121-139, 1992.
75. Eastman A: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells 2: 275-280, 1990.
76. Cheng YC and Nakayama K: Effects of 5-fluoro-2′-deoxyuridine on DNA metabolism in HeLa cells. Mol Pharmacol 23: 171-174, 1983.
77. Fram RJ and Kufe DW: Effect of 1-β-D-arabinofurano-sylcytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts. Biochem Pharmacol 34: 2557-2560, 1985.
78. Bergman AM, Kuiper CM, Voorn DA Comijn EM, Myhren F, Sandvold ML, Hendriks HR and Peters GJ: Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines. Biochem Pharmacol 67: 503-511, 2004.
79. Saiko P, Horvath Z, Bauer W, Hoechtl T, Grusch M, Krupitza G, Rauko P, Mader RM, Jaeger W, Schott H, Novotny L, Fritzer-Szekeres M and Szekeres T: In vitro and in vivo antitumor activity of novel amphiphilic dimers consisting of 5-fluorodeoxyuridine and arabinofuranosylcytosine. Int J Oncol 25: 357-364, 2004.